Sareum (LON:SAR) Trading Up 14.3% – Still a Buy?

Sareum Holdings plc (LON:SAR)’s share price rose 14.3% during mid-day trading on Thursday . The stock traded as high as GBX 16 ($0.21) and last traded at GBX 16 ($0.21). Approximately 156,951 shares were traded during trading, a decline of 65% from the average daily volume of 449,301 shares. The stock had previously closed at GBX 14 ($0.19).

Sareum Stock Performance

The company has a market capitalization of £23.47 million, a price-to-earnings ratio of -6.54 and a beta of -1.08. The company’s fifty day simple moving average is GBX 22.14 and its two-hundred day simple moving average is GBX 18.54.

Sareum (LON:SAR) last announced its quarterly earnings data on Thursday, October 23rd. The company reported GBX (2.40) earnings per share for the quarter. Sell-side analysts anticipate that Sareum Holdings plc will post -3.8 EPS for the current year.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.